[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5CMQ5XvugxxiCupkAzWkyj-QH1H_0udfPyo1_QYt9_w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":71,"rows":78},"Central South University",[4],121,false,22,3,652137,11,72,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Schizophrenia",26,{"name":18,"count":19},"Bipolar Disorder",6,{"name":21,"count":22},"Depression",5,{"name":24,"count":25},"Major Depressive Disorder",4,{"name":27,"count":9},"Aortic Dissection",{"name":29,"count":9},"Parkinson Disease",{"name":31,"count":9},"Major Depressive Disorder (MDD)",{"name":33,"count":34},"Lung Cancer Associated With Cystic Airspaces",2,[36,41,46,51,56,61,66],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06161870","Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model","2024-12","individualized vancomycin dosing based on the population pharmacokinetics (PK) model",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06428968","Investigating the Insulin Resistance in Individuals With Type 2 Diabetes","2024-12-31","160 units nasal insulin spray",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06937476","Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","2026-04-08","Escitalopram",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05838573","Metformin Treatment on Cognitive Impairment of Schizophrenia","2026-12-12","Metformin treatment",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07593170","AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents","2026-12-20","AKK",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06749470","A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules","2026-12-31","Jieyu Chufan",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07045142","Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients","2027-12-31","Atorvastatin",[72,73,74,75,76,77],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[79,103,121,144,162,183,205,288,313,346,364,386,409,433,458,476,500,526,544,571,589,614,640,668,686,704,748,774,799,817,844,862,888,906,927,952,970,994,1012,1037,1062,1085,1119,1147,1182,1211,1229,1258,1276,1301,1327,1352,1376,1394,1420,1438,1456,1482,1500,1518],{"intervention":65,"totalTrials":80,"cells":81},1,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":101},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":84},[],{"trials":90,"activeCount":84},[],{"trials":92,"activeCount":80,"soonestReadout":64},[93],{"nctId":62,"briefTitle":63,"status":94,"phases":95,"primaryCompletion":64,"completion":64,"start":96,"enrollment":97,"conditions":98,"interventions":99},"NOT_YET_RECRUITING",[76],"2024-12-22",480,[31],[65,100],"Jieyu Chufan Capsules simulant",{"trials":102,"activeCount":84},[],{"intervention":100,"totalTrials":80,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":119},{"trials":106,"activeCount":84},[],{"trials":108,"activeCount":84},[],{"trials":110,"activeCount":84},[],{"trials":112,"activeCount":84},[],{"trials":114,"activeCount":80,"soonestReadout":64},[115],{"nctId":62,"briefTitle":63,"status":94,"phases":116,"primaryCompletion":64,"completion":64,"start":96,"enrollment":97,"conditions":117,"interventions":118},[76],[31],[65,100],{"trials":120,"activeCount":84},[],{"intervention":40,"totalTrials":80,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":142},{"trials":124,"activeCount":84},[],{"trials":126,"activeCount":84},[],{"trials":128,"activeCount":84},[],{"trials":130,"activeCount":84},[],{"trials":132,"activeCount":80,"soonestReadout":39},[133],{"nctId":37,"briefTitle":38,"status":134,"phases":135,"primaryCompletion":39,"completion":39,"start":136,"enrollment":137,"conditions":138,"interventions":140},"RECRUITING",[76],"2021-01-01",112,[139],"Severe Infection",[40,141],"empirical vancomycin dosing",{"trials":143,"activeCount":84},[],{"intervention":141,"totalTrials":80,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":160},{"trials":147,"activeCount":84},[],{"trials":149,"activeCount":84},[],{"trials":151,"activeCount":84},[],{"trials":153,"activeCount":84},[],{"trials":155,"activeCount":80,"soonestReadout":39},[156],{"nctId":37,"briefTitle":38,"status":134,"phases":157,"primaryCompletion":39,"completion":39,"start":136,"enrollment":137,"conditions":158,"interventions":159},[76],[139],[40,141],{"trials":161,"activeCount":84},[],{"intervention":55,"totalTrials":80,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":179,"NA":181},{"trials":165,"activeCount":84},[],{"trials":167,"activeCount":84},[],{"trials":169,"activeCount":84},[],{"trials":171,"activeCount":80,"soonestReadout":54},[172],{"nctId":52,"briefTitle":53,"status":134,"phases":173,"primaryCompletion":54,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},[75],"2027-06-30","2023-05-08",120,[15],[55],{"trials":180,"activeCount":84},[],{"trials":182,"activeCount":84},[],{"intervention":70,"totalTrials":80,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":201,"NA":203},{"trials":186,"activeCount":84},[],{"trials":188,"activeCount":84},[],{"trials":190,"activeCount":84},[],{"trials":192,"activeCount":80,"soonestReadout":69},[193],{"nctId":67,"briefTitle":68,"status":134,"phases":194,"primaryCompletion":69,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},[75],"2028-06-01","2025-07-01",400,[15],[70,200],"Metformin",{"trials":202,"activeCount":84},[],{"trials":204,"activeCount":84},[],{"intervention":206,"totalTrials":207,"cells":208},"metformin",7,{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":221,"NA":268},{"trials":210,"activeCount":84},[],{"trials":212,"activeCount":84},[],{"trials":214,"activeCount":84},[],{"trials":216,"activeCount":80,"soonestReadout":69},[217],{"nctId":67,"briefTitle":68,"status":134,"phases":218,"primaryCompletion":69,"completion":195,"start":196,"enrollment":197,"conditions":219,"interventions":220},[75],[15],[70,200],{"trials":222,"activeCount":84},[223,235,247,258],{"nctId":224,"briefTitle":225,"status":226,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT01778244","Metformin for Treatment of Antipsychotic-induced Dyslipidemia","COMPLETED",[76],"2011-12","2012-06","2008-11",162,[233],"Dyslipidemia",[206],{"nctId":236,"briefTitle":237,"status":238,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":246},"NCT03629639","Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism","UNKNOWN",[76],"2020-09-01","2020-12-01","2018-09-01",80,[245],"Psoriasis Vulgaris With Metabolic Disorders",[200],{"nctId":248,"briefTitle":249,"status":226,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT01206153","Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients",[76],"2010-01","2010-03","2008-06",84,[256],"Amenorrhea",[206],{"nctId":259,"briefTitle":260,"status":226,"phases":261,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":267},"NCT00451399","Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain",[76],"2006-12","2004-10",128,[266],"Weight Gain",[206],{"trials":269,"activeCount":84},[270,280],{"nctId":271,"briefTitle":272,"status":273,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":84,"conditions":278,"interventions":279},"NCT01423487","Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea","WITHDRAWN",[77],"2013-02","2013-08","2011-08",[266,256],[200],{"nctId":281,"briefTitle":282,"status":238,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":243,"conditions":286,"interventions":287},"NCT03271866","Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome",[77],"2023-12-31","2017-08-28",[15],[206],{"intervention":60,"totalTrials":80,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":291,"activeCount":84},[],{"trials":293,"activeCount":84},[],{"trials":295,"activeCount":80,"soonestReadout":59},[296],{"nctId":57,"briefTitle":58,"status":94,"phases":297,"primaryCompletion":59,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":306},[74],"2027-02-12","2026-06-06",100,[302,303,304,305],"Obesity","Obese Adolescents","Obese Children and Adolescents","Akkermansia Muciniphila",[60],{"trials":308,"activeCount":84},[],{"trials":310,"activeCount":84},[],{"trials":312,"activeCount":84},[],{"intervention":50,"totalTrials":34,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":316,"activeCount":84},[],{"trials":318,"activeCount":84},[],{"trials":320,"activeCount":84},[],{"trials":322,"activeCount":84},[],{"trials":324,"activeCount":84},[],{"trials":326,"activeCount":80,"soonestReadout":49},[327,336],{"nctId":328,"briefTitle":329,"status":226,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT04977232","Adjunctive Game Intervention for Anhedonia in MDD Patients",[77],"2022-12-31","2021-09-09",50,[21],[50],{"nctId":47,"briefTitle":48,"status":337,"phases":338,"primaryCompletion":49,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"ACTIVE_NOT_RECRUITING",[77],"2026-05-01","2025-05-08",108,[31,343],"Rumination",[50,345],"Aripiprazole 5mg",{"intervention":345,"totalTrials":80,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":358},{"trials":349,"activeCount":84},[],{"trials":351,"activeCount":84},[],{"trials":353,"activeCount":84},[],{"trials":355,"activeCount":84},[],{"trials":357,"activeCount":84},[],{"trials":359,"activeCount":80,"soonestReadout":49},[360],{"nctId":47,"briefTitle":48,"status":337,"phases":361,"primaryCompletion":49,"completion":339,"start":340,"enrollment":341,"conditions":362,"interventions":363},[77],[31,343],[50,345],{"intervention":45,"totalTrials":80,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":367,"activeCount":84},[],{"trials":369,"activeCount":84},[],{"trials":371,"activeCount":84},[],{"trials":373,"activeCount":84},[],{"trials":375,"activeCount":84},[],{"trials":377,"activeCount":80,"soonestReadout":44},[378],{"nctId":42,"briefTitle":43,"status":134,"phases":379,"primaryCompletion":44,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},[77],"2025-06-30","2024-09-06",30,[384],"Type 2 Diabetes",[45],{"intervention":387,"totalTrials":80,"cells":388},"Donepezil",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":407},{"trials":390,"activeCount":84},[],{"trials":392,"activeCount":84},[],{"trials":394,"activeCount":84},[],{"trials":396,"activeCount":84},[],{"trials":398,"activeCount":84},[399],{"nctId":400,"briefTitle":401,"status":238,"phases":402,"primaryCompletion":229,"completion":229,"start":403,"enrollment":243,"conditions":404,"interventions":406},"NCT01490567","A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia",[76],"2011-06",[405,15],"Impaired Cognition",[387],{"trials":408,"activeCount":84},[],{"intervention":410,"totalTrials":80,"cells":411},"minocycline",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":431},{"trials":413,"activeCount":84},[],{"trials":415,"activeCount":84},[],{"trials":417,"activeCount":84},[],{"trials":419,"activeCount":84},[],{"trials":421,"activeCount":84},[422],{"nctId":423,"briefTitle":424,"status":226,"phases":425,"primaryCompletion":426,"completion":228,"start":427,"enrollment":428,"conditions":429,"interventions":430},"NCT01493622","The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia",[76],"2011-11","2010-06",78,[15],[410],{"trials":432,"activeCount":84},[],{"intervention":434,"totalTrials":80,"cells":435},"risperidone oral solution",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":444,"NA":456},{"trials":437,"activeCount":84},[],{"trials":439,"activeCount":84},[],{"trials":441,"activeCount":84},[],{"trials":443,"activeCount":84},[],{"trials":445,"activeCount":84},[446],{"nctId":447,"briefTitle":448,"status":226,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT00859872","Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia",[76],"2009-03","2008-08",198,[15],[434,455],"haloperidol",{"trials":457,"activeCount":84},[],{"intervention":455,"totalTrials":80,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":474},{"trials":461,"activeCount":84},[],{"trials":463,"activeCount":84},[],{"trials":465,"activeCount":84},[],{"trials":467,"activeCount":84},[],{"trials":469,"activeCount":84},[470],{"nctId":447,"briefTitle":448,"status":226,"phases":471,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":472,"interventions":473},[76],[15],[434,455],{"trials":475,"activeCount":84},[],{"intervention":477,"totalTrials":80,"cells":478},"Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":498},{"trials":480,"activeCount":84},[],{"trials":482,"activeCount":84},[],{"trials":484,"activeCount":84},[],{"trials":486,"activeCount":84},[],{"trials":488,"activeCount":84},[489],{"nctId":490,"briefTitle":491,"status":226,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":497},"NCT00654576","Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia",[76],"2007-12","2005-02",1400,[15],[477],{"trials":499,"activeCount":84},[],{"intervention":501,"totalTrials":80,"cells":502},"Agomelatine",{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":511,"NA":524},{"trials":504,"activeCount":84},[],{"trials":506,"activeCount":84},[],{"trials":508,"activeCount":84},[],{"trials":510,"activeCount":84},[],{"trials":512,"activeCount":84},[513],{"nctId":514,"briefTitle":515,"status":226,"phases":516,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT04589143","A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine",[76],"2022-12-30","2023-01-30","2020-10-01",137,[24],[501,523],"Placebos",{"trials":525,"activeCount":84},[],{"intervention":523,"totalTrials":80,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":542},{"trials":529,"activeCount":84},[],{"trials":531,"activeCount":84},[],{"trials":533,"activeCount":84},[],{"trials":535,"activeCount":84},[],{"trials":537,"activeCount":84},[538],{"nctId":514,"briefTitle":515,"status":226,"phases":539,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":540,"interventions":541},[76],[24],[501,523],{"trials":543,"activeCount":84},[],{"intervention":545,"totalTrials":80,"cells":546},"olmesartan medoxomil",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":569},{"trials":548,"activeCount":84},[],{"trials":550,"activeCount":84},[],{"trials":552,"activeCount":84},[],{"trials":554,"activeCount":84},[],{"trials":556,"activeCount":84},[557],{"nctId":558,"briefTitle":559,"status":226,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT01907373","Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers",[76],"2009-09","2009-10","2009-08",12,[566],"Drug Interaction of Olmesartan in Healthy Chinese Volunteers",[545,568],"olmesartan medoxomil+probenecid",{"trials":570,"activeCount":84},[],{"intervention":568,"totalTrials":80,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":587},{"trials":574,"activeCount":84},[],{"trials":576,"activeCount":84},[],{"trials":578,"activeCount":84},[],{"trials":580,"activeCount":84},[],{"trials":582,"activeCount":84},[583],{"nctId":558,"briefTitle":559,"status":226,"phases":584,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":585,"interventions":586},[76],[566],[545,568],{"trials":588,"activeCount":84},[],{"intervention":590,"totalTrials":80,"cells":591},"Remifentanil",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":612},{"trials":593,"activeCount":84},[],{"trials":595,"activeCount":84},[],{"trials":597,"activeCount":84},[],{"trials":599,"activeCount":84},[],{"trials":601,"activeCount":84},[602],{"nctId":603,"briefTitle":604,"status":238,"phases":605,"primaryCompletion":606,"start":607,"enrollment":608,"conditions":609,"interventions":611},"NCT01761149","Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy",[76],"2013-03","2012-12",60,[610],"Nodular Goiter",[590],{"trials":613,"activeCount":84},[],{"intervention":615,"totalTrials":80,"cells":616},"Cyclosporine A, Tacrolimus, Sirolimus",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":638},{"trials":618,"activeCount":84},[],{"trials":620,"activeCount":84},[],{"trials":622,"activeCount":84},[],{"trials":624,"activeCount":84},[],{"trials":626,"activeCount":84},[627],{"nctId":628,"briefTitle":629,"status":238,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":637},"NCT01699360","The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients",[76],"2013-09","2013-12","2012-09",600,[636],"Kidney Transplantation",[615],{"trials":639,"activeCount":84},[],{"intervention":641,"totalTrials":80,"cells":642},"Remimazolam",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":666},{"trials":644,"activeCount":84},[],{"trials":646,"activeCount":84},[],{"trials":648,"activeCount":84},[],{"trials":650,"activeCount":84},[],{"trials":652,"activeCount":84},[653],{"nctId":654,"briefTitle":655,"status":226,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT06513923","Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia",[76],"2023-09-30","2023-10-31","2023-02-01",136,[662],"Hip Fracture",[641,664,665],"Flumazenil","Propofol",{"trials":667,"activeCount":84},[],{"intervention":664,"totalTrials":80,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":676,"PHASE4":678,"NA":684},{"trials":671,"activeCount":84},[],{"trials":673,"activeCount":84},[],{"trials":675,"activeCount":84},[],{"trials":677,"activeCount":84},[],{"trials":679,"activeCount":84},[680],{"nctId":654,"briefTitle":655,"status":226,"phases":681,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":682,"interventions":683},[76],[662],[641,664,665],{"trials":685,"activeCount":84},[],{"intervention":665,"totalTrials":80,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":702},{"trials":689,"activeCount":84},[],{"trials":691,"activeCount":84},[],{"trials":693,"activeCount":84},[],{"trials":695,"activeCount":84},[],{"trials":697,"activeCount":84},[698],{"nctId":654,"briefTitle":655,"status":226,"phases":699,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":700,"interventions":701},[76],[662],[641,664,665],{"trials":703,"activeCount":84},[],{"intervention":705,"totalTrials":9,"cells":706},"Sulforaphane",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":708,"activeCount":84},[],{"trials":710,"activeCount":84},[],{"trials":712,"activeCount":84},[713,725,734],{"nctId":714,"briefTitle":715,"status":238,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT04246905","A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression",[74],"2021-12-31","2020-07-15",90,[721],"Depressive Disorder",[723,724],"sulforaphane","selective 5 - HT reuptake inhibitors",{"nctId":726,"briefTitle":727,"status":226,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":733},"NCT04521868","A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients",[74],"2022-08-12","2020-08-31",125,[15],[705],{"nctId":735,"briefTitle":736,"status":238,"phases":737,"primaryCompletion":738,"completion":284,"start":739,"enrollment":300,"conditions":740,"interventions":741},"NCT05084365","A 6-month Study to Evaluate Sulforaphane Effects in PD Patients",[74],"2023-11-15","2021-11-28",[29],[705],{"trials":743,"activeCount":84},[],{"trials":745,"activeCount":84},[],{"trials":747,"activeCount":84},[],{"intervention":749,"totalTrials":80,"cells":750},"TSER",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":752,"activeCount":84},[],{"trials":754,"activeCount":84},[],{"trials":756,"activeCount":84},[757],{"nctId":758,"briefTitle":759,"status":226,"phases":760,"primaryCompletion":761,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":767},"NCT02204306","Genotype Guided Chemotherapy in Gastric Cancer Patients",[74],"2016-03","2016-12","2014-04",330,[766],"Metastatic Gastric Cancer",[749],{"trials":769,"activeCount":84},[],{"trials":771,"activeCount":84},[],{"trials":773,"activeCount":84},[],{"intervention":775,"totalTrials":80,"cells":776},"Acitretin",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":778,"activeCount":84},[],{"trials":780,"activeCount":84},[],{"trials":782,"activeCount":84},[783],{"nctId":784,"briefTitle":785,"status":238,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":790,"interventions":792},"NCT02715960","Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules",[74],"2017-12","2015-12",500,[791],"Psoriasis Vulgaris",[775],{"trials":794,"activeCount":84},[],{"trials":796,"activeCount":84},[],{"trials":798,"activeCount":84},[],{"intervention":724,"totalTrials":80,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":802,"activeCount":84},[],{"trials":804,"activeCount":84},[],{"trials":806,"activeCount":84},[807],{"nctId":714,"briefTitle":715,"status":238,"phases":808,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":809,"interventions":810},[74],[721],[723,724],{"trials":812,"activeCount":84},[],{"trials":814,"activeCount":84},[],{"trials":816,"activeCount":84},[],{"intervention":818,"totalTrials":80,"cells":819},"loading dose atorvastatin",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":821,"activeCount":84},[],{"trials":823,"activeCount":84},[],{"trials":825,"activeCount":84},[826],{"nctId":827,"briefTitle":828,"status":238,"phases":829,"primaryCompletion":632,"completion":830,"start":607,"enrollment":831,"conditions":832,"interventions":836},"NCT01761656","Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR",[74],"2014-02",180,[833,834,835],"Stable Angina","Unstable Angina","Acute Non-ST-segment Elevation Myocardial Infarction",[818,837],"conventional dose atorvastatin",{"trials":839,"activeCount":84},[],{"trials":841,"activeCount":84},[],{"trials":843,"activeCount":84},[],{"intervention":837,"totalTrials":80,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":847,"activeCount":84},[],{"trials":849,"activeCount":84},[],{"trials":851,"activeCount":84},[852],{"nctId":827,"briefTitle":828,"status":238,"phases":853,"primaryCompletion":632,"completion":830,"start":607,"enrollment":831,"conditions":854,"interventions":855},[74],[833,834,835],[818,837],{"trials":857,"activeCount":84},[],{"trials":859,"activeCount":84},[],{"trials":861,"activeCount":84},[],{"intervention":863,"totalTrials":80,"cells":864},"Propranolol Hydrochloride",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":866,"activeCount":84},[],{"trials":868,"activeCount":84},[],{"trials":870,"activeCount":84},[871],{"nctId":872,"briefTitle":873,"status":238,"phases":874,"primaryCompletion":875,"completion":381,"start":876,"enrollment":877,"conditions":878,"interventions":880},"NCT04493489","Propranolol Adjuvant Treatment of Bladder Cancer",[74],"2023-09-06","2020-09-06",242,[879],"Bladder Cancer",[863,881],"BCG",{"trials":883,"activeCount":84},[],{"trials":885,"activeCount":84},[],{"trials":887,"activeCount":84},[],{"intervention":881,"totalTrials":80,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":891,"activeCount":84},[],{"trials":893,"activeCount":84},[],{"trials":895,"activeCount":84},[896],{"nctId":872,"briefTitle":873,"status":238,"phases":897,"primaryCompletion":875,"completion":381,"start":876,"enrollment":877,"conditions":898,"interventions":899},[74],[879],[863,881],{"trials":901,"activeCount":84},[],{"trials":903,"activeCount":84},[],{"trials":905,"activeCount":84},[],{"intervention":907,"totalTrials":80,"cells":908},"Methotrexate",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":910,"activeCount":84},[],{"trials":912,"activeCount":84},[],{"trials":914,"activeCount":84},[915],{"nctId":916,"briefTitle":917,"status":238,"phases":918,"primaryCompletion":787,"completion":787,"start":788,"enrollment":197,"conditions":919,"interventions":920},"NCT02715947","Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate",[74],[791],[907],{"trials":922,"activeCount":84},[],{"trials":924,"activeCount":84},[],{"trials":926,"activeCount":84},[],{"intervention":928,"totalTrials":80,"cells":929},"Langenlianqiao",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":931,"activeCount":84},[],{"trials":933,"activeCount":84},[934],{"nctId":935,"briefTitle":936,"status":226,"phases":937,"primaryCompletion":517,"completion":331,"start":938,"enrollment":939,"conditions":940,"interventions":942},"NCT06355193","The Use of Isatidis Root and Forsythia Oral Liquid for the Treatment of Mild Cases of COVID-19: A Trial Clinical Study",[73],"2022-11-01",253,[941],"Treatment of Mild Cases of COVID-19",[928,943],"LianhuaQingWen",{"trials":945,"activeCount":84},[],{"trials":947,"activeCount":84},[],{"trials":949,"activeCount":84},[],{"trials":951,"activeCount":84},[],{"intervention":943,"totalTrials":80,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":955,"activeCount":84},[],{"trials":957,"activeCount":84},[958],{"nctId":935,"briefTitle":936,"status":226,"phases":959,"primaryCompletion":517,"completion":331,"start":938,"enrollment":939,"conditions":960,"interventions":961},[73],[941],[928,943],{"trials":963,"activeCount":84},[],{"trials":965,"activeCount":84},[],{"trials":967,"activeCount":84},[],{"trials":969,"activeCount":84},[],{"intervention":971,"totalTrials":80,"cells":972},"paracetamol oral solution",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":974,"activeCount":84},[],{"trials":976,"activeCount":84},[977],{"nctId":978,"briefTitle":979,"status":226,"phases":980,"primaryCompletion":981,"completion":981,"start":981,"enrollment":19,"conditions":982,"interventions":984},"NCT02095704","Pharmacokinetics of a Standard Paracetamol Tablet and Oral Solution After Oral Administration in Chinese Healthy Volunteers",[73],"2013-05",[983],"Focus of Study: Pharmacokinetics Analysis, in Vivo Dissolution Studies",[971,985],"paracetamol",{"trials":987,"activeCount":84},[],{"trials":989,"activeCount":84},[],{"trials":991,"activeCount":84},[],{"trials":993,"activeCount":84},[],{"intervention":985,"totalTrials":80,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":84},[],{"trials":999,"activeCount":84},[1000],{"nctId":978,"briefTitle":979,"status":226,"phases":1001,"primaryCompletion":981,"completion":981,"start":981,"enrollment":19,"conditions":1002,"interventions":1003},[73],[983],[971,985],{"trials":1005,"activeCount":84},[],{"trials":1007,"activeCount":84},[],{"trials":1009,"activeCount":84},[],{"trials":1011,"activeCount":84},[],{"intervention":1013,"totalTrials":80,"cells":1014},"PD-1 knockout engineered T cells",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1016,"activeCount":84},[],{"trials":1018,"activeCount":84},[1019],{"nctId":1020,"briefTitle":1021,"status":238,"phases":1022,"primaryCompletion":1023,"completion":44,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT04417764","TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.",[73],"2024-12-30","2019-06-20",10,[1027],"Advanced Hepatocellular Carcinoma",[1013],{"trials":1030,"activeCount":84},[],{"trials":1032,"activeCount":84},[],{"trials":1034,"activeCount":84},[],{"trials":1036,"activeCount":84},[],{"intervention":1038,"totalTrials":80,"cells":1039},"Mesenchymal Stem Cells",{"EARLY_PHASE1":1040,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1041,"activeCount":84},[1042],{"nctId":1043,"briefTitle":1044,"status":238,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":564,"conditions":1049,"interventions":1051},"NCT03765957","Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells",[72],"2020-07-31","2021-06-01","2019-02-20",[1050],"Psoriasis",[1038],{"trials":1053,"activeCount":84},[],{"trials":1055,"activeCount":84},[],{"trials":1057,"activeCount":84},[],{"trials":1059,"activeCount":84},[],{"trials":1061,"activeCount":84},[],{"intervention":1063,"totalTrials":80,"cells":1064},"Propranolol",{"EARLY_PHASE1":1065,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1066,"activeCount":84},[1067],{"nctId":1068,"briefTitle":1069,"status":238,"phases":1070,"primaryCompletion":240,"completion":240,"start":1071,"enrollment":243,"conditions":1072,"interventions":1074},"NCT03245554","Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol",[72],"2018-05-01",[1073],"Gastrointestinal Cancer",[1063],{"trials":1076,"activeCount":84},[],{"trials":1078,"activeCount":84},[],{"trials":1080,"activeCount":84},[],{"trials":1082,"activeCount":84},[],{"trials":1084,"activeCount":84},[],{"intervention":1086,"totalTrials":34,"cells":1087},"Antipsychotic drugs",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1089,"activeCount":84},[],{"trials":1091,"activeCount":84},[],{"trials":1093,"activeCount":84},[],{"trials":1095,"activeCount":84},[],{"trials":1097,"activeCount":84},[],{"trials":1099,"activeCount":84},[1100,1112],{"nctId":1101,"briefTitle":1102,"status":226,"phases":1103,"primaryCompletion":1104,"completion":284,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT04218981","Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders",[77],"2023-06-25","2020-01-15",200,[1108],"Common Mental Disorder",[1086,1110,1111],"Mood stabilizer","Paroxetine",{"nctId":1113,"briefTitle":1114,"status":226,"phases":1115,"primaryCompletion":658,"completion":1116,"start":332,"enrollment":1106,"conditions":1117,"interventions":1118},"NCT05039489","A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia",[77],"2023-11-30",[15],[1086],{"intervention":1111,"totalTrials":34,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1122,"activeCount":84},[],{"trials":1124,"activeCount":84},[],{"trials":1126,"activeCount":84},[],{"trials":1128,"activeCount":84},[],{"trials":1130,"activeCount":84},[],{"trials":1132,"activeCount":84},[1133,1137],{"nctId":1101,"briefTitle":1102,"status":226,"phases":1134,"primaryCompletion":1104,"completion":284,"start":1105,"enrollment":1106,"conditions":1135,"interventions":1136},[77],[1108],[1086,1110,1111],{"nctId":1138,"briefTitle":1139,"status":226,"phases":1140,"primaryCompletion":331,"completion":331,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1146},"NCT03894085","Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging （fMRI） Study With Paroxetine Treatment",[77],"2019-05-30",150,[1144,1145],"Anxiety Disorder","Obsessive-Compulsive Disorder",[1111],{"intervention":1148,"totalTrials":34,"cells":1149},"Risperidone",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1167},{"trials":1151,"activeCount":84},[],{"trials":1153,"activeCount":84},[],{"trials":1155,"activeCount":84},[],{"trials":1157,"activeCount":84},[],{"trials":1159,"activeCount":84},[1160],{"nctId":1161,"briefTitle":1162,"status":238,"phases":1163,"primaryCompletion":251,"start":1164,"enrollment":300,"conditions":1165,"interventions":1166},"NCT00305474","Identification and Treatment of the Liability to Develop Schizophrenia",[76],"2003-12",[15],[1148],{"trials":1168,"activeCount":84},[1169],{"nctId":1170,"briefTitle":1171,"status":238,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":229,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT02137616","Antipsychotic to Treat Psychosis Syndrome",[77],"2014-12",300,[1176],"Psychotic Disorders",[1178,1179,1180,1181],"risperidone","olanzapine","Quetiapine","Aripiprazole",{"intervention":1180,"totalTrials":34,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1185,"activeCount":84},[],{"trials":1187,"activeCount":84},[],{"trials":1189,"activeCount":84},[],{"trials":1191,"activeCount":84},[],{"trials":1193,"activeCount":84},[],{"trials":1195,"activeCount":84},[1196,1207],{"nctId":1197,"briefTitle":1198,"status":238,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT05840861","Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders",[],"2023-08-21","2023-09-05","2020-11-05",59,[24,18],[1206,1180],"Vortioxetine",{"nctId":1170,"briefTitle":1171,"status":238,"phases":1208,"primaryCompletion":1173,"completion":1173,"start":229,"enrollment":1174,"conditions":1209,"interventions":1210},[77],[1176],[1178,1179,1180,1181],{"intervention":1110,"totalTrials":80,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1214,"activeCount":84},[],{"trials":1216,"activeCount":84},[],{"trials":1218,"activeCount":84},[],{"trials":1220,"activeCount":84},[],{"trials":1222,"activeCount":84},[],{"trials":1224,"activeCount":84},[1225],{"nctId":1101,"briefTitle":1102,"status":226,"phases":1226,"primaryCompletion":1104,"completion":284,"start":1105,"enrollment":1106,"conditions":1227,"interventions":1228},[77],[1108],[1086,1110,1111],{"intervention":1230,"totalTrials":80,"cells":1231},"Antibody-Drug Conjugate",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1233,"activeCount":84},[],{"trials":1235,"activeCount":84},[],{"trials":1237,"activeCount":84},[],{"trials":1239,"activeCount":84},[],{"trials":1241,"activeCount":84},[],{"trials":1243,"activeCount":84},[1244],{"nctId":1245,"briefTitle":1246,"status":226,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1256},"NCT05349383","Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities",[],"2022-05-22","2022-06-01","2022-04-22",24618,[1253,1254,1255],"Sepsis (SMQ)","Opportunistic Infections","Agranulocytosis",[1230,1257],"Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate",{"intervention":1257,"totalTrials":80,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1270},{"trials":1261,"activeCount":84},[],{"trials":1263,"activeCount":84},[],{"trials":1265,"activeCount":84},[],{"trials":1267,"activeCount":84},[],{"trials":1269,"activeCount":84},[],{"trials":1271,"activeCount":84},[1272],{"nctId":1245,"briefTitle":1246,"status":226,"phases":1273,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1274,"interventions":1275},[],[1253,1254,1255],[1230,1257],{"intervention":1277,"totalTrials":80,"cells":1278},"rosiglitazone",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":84},[],{"trials":1282,"activeCount":84},[],{"trials":1284,"activeCount":84},[],{"trials":1286,"activeCount":84},[],{"trials":1288,"activeCount":84},[],{"trials":1290,"activeCount":84},[1291],{"nctId":1292,"briefTitle":1293,"status":226,"phases":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT00501488","Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response",[],"2007-02","2006-03",42,[1299],"Diabetes Mellitus",[1277],{"intervention":1302,"totalTrials":80,"cells":1303},"Protein Kinase Inhibitor",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1305,"activeCount":84},[],{"trials":1307,"activeCount":84},[],{"trials":1309,"activeCount":84},[],{"trials":1311,"activeCount":84},[],{"trials":1313,"activeCount":84},[],{"trials":1315,"activeCount":84},[1316],{"nctId":1317,"briefTitle":1318,"status":238,"phases":1319,"primaryCompletion":1320,"completion":1321,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1326},"NCT05430126","Hepatotoxicity Related to Protein Kinase Inhibitors",[],"2022-07-20","2022-08-10","2022-06-19",600000,[1325],"Cancer",[1302],{"intervention":1328,"totalTrials":80,"cells":1329},"Gene analysis",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1340},{"trials":1331,"activeCount":84},[],{"trials":1333,"activeCount":84},[],{"trials":1335,"activeCount":84},[],{"trials":1337,"activeCount":84},[],{"trials":1339,"activeCount":84},[],{"trials":1341,"activeCount":84},[1342],{"nctId":1343,"briefTitle":1344,"status":226,"phases":1345,"primaryCompletion":1346,"completion":1347,"start":1348,"enrollment":22,"conditions":1349,"interventions":1351},"NCT01878604","Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia",[],"2014-10","2015-01","2001-10",[1350],"Homozygous Familial Hypercholesterolemia",[1328],{"intervention":1353,"totalTrials":80,"cells":1354},"Bifico",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1356,"activeCount":84},[],{"trials":1358,"activeCount":84},[],{"trials":1360,"activeCount":84},[],{"trials":1362,"activeCount":84},[],{"trials":1364,"activeCount":84},[],{"trials":1366,"activeCount":84},[1367],{"nctId":1368,"briefTitle":1369,"status":226,"phases":1370,"primaryCompletion":1371,"completion":1372,"start":1373,"enrollment":660,"conditions":1374,"interventions":1375},"NCT03379597","A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder",[77],"2021-05-31","2021-06-30","2017-11-30",[15,18],[1353],{"intervention":1206,"totalTrials":80,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1379,"activeCount":84},[],{"trials":1381,"activeCount":84},[],{"trials":1383,"activeCount":84},[],{"trials":1385,"activeCount":84},[],{"trials":1387,"activeCount":84},[],{"trials":1389,"activeCount":84},[1390],{"nctId":1197,"briefTitle":1198,"status":238,"phases":1391,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1392,"interventions":1393},[],[24,18],[1206,1180],{"intervention":1395,"totalTrials":80,"cells":1396},"antipsychotic medications",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1398,"activeCount":84},[],{"trials":1400,"activeCount":84},[],{"trials":1402,"activeCount":84},[],{"trials":1404,"activeCount":84},[],{"trials":1406,"activeCount":84},[],{"trials":1408,"activeCount":84},[1409],{"nctId":1410,"briefTitle":1411,"status":226,"phases":1412,"primaryCompletion":1372,"completion":1372,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1417},"NCT03451734","Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients",[],"2018-01-23",2000,[15,1416],"Metabolic Syndrome",[1395,1418,1419],"adjunctive group","metformin and lifestyle intervention",{"intervention":1418,"totalTrials":80,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1423,"activeCount":84},[],{"trials":1425,"activeCount":84},[],{"trials":1427,"activeCount":84},[],{"trials":1429,"activeCount":84},[],{"trials":1431,"activeCount":84},[],{"trials":1433,"activeCount":84},[1434],{"nctId":1410,"briefTitle":1411,"status":226,"phases":1435,"primaryCompletion":1372,"completion":1372,"start":1413,"enrollment":1414,"conditions":1436,"interventions":1437},[],[15,1416],[1395,1418,1419],{"intervention":1419,"totalTrials":80,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1441,"activeCount":84},[],{"trials":1443,"activeCount":84},[],{"trials":1445,"activeCount":84},[],{"trials":1447,"activeCount":84},[],{"trials":1449,"activeCount":84},[],{"trials":1451,"activeCount":84},[1452],{"nctId":1410,"briefTitle":1411,"status":226,"phases":1453,"primaryCompletion":1372,"completion":1372,"start":1413,"enrollment":1414,"conditions":1454,"interventions":1455},[],[15,1416],[1395,1418,1419],{"intervention":1457,"totalTrials":80,"cells":1458},"suanzaoren decoction",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1460,"activeCount":84},[],{"trials":1462,"activeCount":84},[],{"trials":1464,"activeCount":84},[],{"trials":1466,"activeCount":84},[],{"trials":1468,"activeCount":84},[],{"trials":1470,"activeCount":84},[1471],{"nctId":1472,"briefTitle":1473,"status":226,"phases":1474,"primaryCompletion":658,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1480},"NCT06452953","Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder",[77],"2024-03-01","2020-09-10",85,[1479],"Chronic Insomnia Disorder",[1457,1481],"Eszopiclone 1 mg",{"intervention":1481,"totalTrials":80,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1485,"activeCount":84},[],{"trials":1487,"activeCount":84},[],{"trials":1489,"activeCount":84},[],{"trials":1491,"activeCount":84},[],{"trials":1493,"activeCount":84},[],{"trials":1495,"activeCount":84},[1496],{"nctId":1472,"briefTitle":1473,"status":226,"phases":1497,"primaryCompletion":658,"completion":1475,"start":1476,"enrollment":1477,"conditions":1498,"interventions":1499},[77],[1479],[1457,1481],{"intervention":1179,"totalTrials":80,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1503,"activeCount":84},[],{"trials":1505,"activeCount":84},[],{"trials":1507,"activeCount":84},[],{"trials":1509,"activeCount":84},[],{"trials":1511,"activeCount":84},[],{"trials":1513,"activeCount":84},[1514],{"nctId":1170,"briefTitle":1171,"status":238,"phases":1515,"primaryCompletion":1173,"completion":1173,"start":229,"enrollment":1174,"conditions":1516,"interventions":1517},[77],[1176],[1178,1179,1180,1181],{"intervention":1181,"totalTrials":80,"cells":1519},{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1521,"activeCount":84},[],{"trials":1523,"activeCount":84},[],{"trials":1525,"activeCount":84},[],{"trials":1527,"activeCount":84},[],{"trials":1529,"activeCount":84},[],{"trials":1531,"activeCount":84},[1532],{"nctId":1170,"briefTitle":1171,"status":238,"phases":1533,"primaryCompletion":1173,"completion":1173,"start":229,"enrollment":1174,"conditions":1534,"interventions":1535},[77],[1176],[1178,1179,1180,1181]]